Search results - 6 results
Risks related to a possible reduction of the waiting period for dogs after rabies antibody titration to 30 days compared with 90 days of the current EU legislative regime.
before the development of immunity (21 days post-vaccination). Using published data on the incubation period for experimental and field cases in dogs and considering the rabies incidence data in certain ...
Evaluation of dog vaccination schemes against rabies in Kinshasa, Democratic Republic of the Congo.
site. The turnover rate of dogs was used to assess their population dynamics in two low-roaming (<25 % of dogs are roaming) and in two high-roaming zones (>75 % of dogs are roaming). The ...
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review.
case reported in a cow during 2009. A long-term ORV barrier program in the USA using RABORAL V- RG is preventing substantial geographic expansion of the raccoon rabies virus variant. RABORAL V- RG has ...
Impact of caspase-1/11,-3,-7, or IL-1/IL-18 deficiency on rabies virus-induced macrophage cell death and onset of disease.
been used as an oral vaccine for animals. Infection of Mf4/4 macrophages with both strains led to caspase-1 activation and IL-1 and IL-18 production, as well as activation of caspases-3,-7,-8, and-9. ...
Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection.
unable to protect mice from lethal challenge. Anti-rabies VHH and vaccine act synergistically to protect mice after rabies virus exposure, which further validates the possible use of anti-rabies VHH for ...
Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.
antibodies, also called Nanobodies. The therapeutic potential of anti-rabies VHH was examined in a mouse model using intranasal challenge with a lethal dose of rabies virus. Anti-rabies VHH were administered ...